

Transparency Notification Tolefi SA (Article 14 of the Law of 2 August 2007)

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences (C3BS) (*NYSE Euronext Brussels and Paris: CARD*), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, today announces it has received a transparency declaration from Tolefi SA in accordance with the Belgian Law of 2nd May 2007 concerning disclosure of major holdings in issuers whose shares are admitted to trading on a Belgian regulated market.

As of today, the Company's share capital amounts to EUR 24,597,080.63 and is represented by a total 7,035,387 shares (each share given one voting right).

Transparency notification from Tolefi SA

Cardio3 BioSciences received on 24 July 2014 a transparency notification from Tolefi SA, having passed, on 30 June 2014, the 35% threshold, as a consequence to the capital increase completed on 30 June 2014, fully subscribed by Medisun International Limited.

- Reason for notification: passive crossing of the threshold
- Notification by a parent company or controlling person.
- Person holdings notification:

Name	Address
TOLEFI SA	27, Drève de Carloo, 1180 Bruxelles
Serge GOBLET	
Isabelle THOUMYRE	

Voting rights	Previous notification	Post the transaction			
	# voting rights	# voting rights		% voting rights	
Holder of voting rights		Attached to shares	Non related securities	Attached to shares	Non related securities
TOLEFI SA	2,267,844	2,267,844	-	32.26%	-
Serge GOBLET		-	-	0	-
Isabelle THOUMYRE		-	-	0	-
TOTAL		2,267,844	0	32.26%	0.00%

Tolefi SA is a family holding company 100% owned by Mr. Serge Goblet and his wife Isabelle Thoumyre. The company also holds 2,504 warrants giving 2,504 voting rights.

*** END ***

For more information, please contact:

Cardio3 BioSciences

Patrick Jeanmart, CFO

Julie Grade, Corporate Communications Manager

Citigate Dewe Rogerson

Chris Gardner

www.c3bs.com

Tel. : +32 10 39 41 00

jgrade@c3bs.com

Tel : +44 (0) 207 638 9571

Chris.Gardner@citigatedr.co.uk**About Cardio3 BioSciences**

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure[®] is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure[®] consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath^{®ez}, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.